The Supreme Court of the United States’ decision in United States v. Arthrex, Inc. gives the U.S. Patent and Trademark Office (USPTO) director the right to review Patent Trial and Appeal Board (PTAB) decisions. However, the decision did not provide much guidance on how to ask the director for a rehearing, how this new rehearing step will work alongside the Precedential Opinion Panel, and what will happen with a backlog of cases that were remanded by the U.S. Court of Appeals for the Federal Circuit now that the justices have issued their ruling in Arthrex. Law360 interviewed Finnegan partner Joshua Goldberg for his thoughts on the decision.
Josh indicated that the current lack of a USPTO director could cause some challenges, as the agency is currently led by someone who was not confirmed by the Senate. He said, “Can the acting director even do anything about this, or do we have to wait until there's a fully appointed new director?”
Read “Arthrex Ruling Leaves Attys Eyeing USPTO for Guidance”
Arthrex v. Smith & Nephew , United States v. Arthrex, Supreme Court of the United States (SCOTUS), Patent Trial and Appeal Board (PTAB), administrative patent judge (APJ)
Press Release
October 6, 2026
Award/Ranking
Finnegan Receives Top Tier Rankings in World Trademark Review’s Inaugural Copyright 1000 2026
September 23, 2026
Press Release
Finnegan Secures Precedential Pro Bono Federal Circuit Victory for AI Whistleblower
September 23, 2026
Commentary
FORUM IP Talks: Dr. Jochen Herr on UPC, FRAND, and Cross-Border Enforcement Topics
September 20, 2026
Commentary
Pepsi's U.S. Trademark Dispute Could Reshape Brand Choices, Lawsuit Strategy, Lawyers Say
September 17, 2026
Commentary
Uncrustables Fame Ruling Sets Up Functionality Fight Over Crimped Edge
September 11, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.